The EIC Transition program aims to bridge the gap between early-stage research and market-ready innovations. Among the 40 selected proposals for this last 2024 extremely competitive call is MeDiCS, a project led by our PI, Prof. José Luis Mascareñas, focused on the clinical development of a new anticancer agent.

In addition to Prof. Mascareñas, the MeDiCS team also includes scientists from the Institute for Biomedical Research Sols-Morreale (IIBM), a joint center of the Spanish National Research Council (CSIC) and the Autonomous University of Madrid (UAM), and the Institute for Research and Innovation in Health (i3S) at the University of Porto, along with support from the companies MyBiotech and Asphalion.

This consortium, led by our research group, has secured €2.5 million to develop its proposal over the next three years.

MeDiCS, short for Anticancer approach based on the Metabolic Disruption of Cancer Stem Cells, focuses on the preclinical potential of a family of ruthenium-based metallic complexes in targeting certain tumors. The current objective is to progress the technology by completing the preclinical phase, a critical step before moving to human clinical trials.